A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)

PHASE2CompletedINTERVENTIONAL

Enrollment

137

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

January 31, 2012

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Erlotinib HCl

Erlotinib 150 mg oral dose once daily.

DRUG

MetMAb

MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks.

DRUG

placebo (0.9 % saline)

Placebo Intravenous infusion every 3 weeks.